Lonza And Vertex Sign A Supply Agreement For Casgevy®

T-Reuters
24 Sep 2024

LONZA GROUP AG :Lonza And Vertex Sign A Long-Term Commercial Supply Agreement For Casgevy® (Exagamglogene Autotemcel).Lonza Group Ag - To Manufacture World'S First Crispr/Cas9 Cell Therapy.Lonza Group Ag - Geleen (Nl) Site Is Now Approved By Fda, Ema And Mhra For Commercial Production Of Casgevy^®.Lonza Group Ag - Casgevy To Be Manufactured At Lonza'S Geleen Facility.Lonza Group Ag - Geleen Site Approved By Fda, Ema, Mhra For Casgevy Production.Lonza Group Ag - Portsmouth Site Expected To Begin Gmp Operations In 2025.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10